Effectiveness and limitations of β-blocker therapy in congenital long-QT syndrome

Arthur J Moss, Wojciech Zareba, W Jackson Hall, Peter J Schwartz, Richard S Crampton, Jesaia Benhorin, G Michael Vincent, Emanuela H Locati, Silvia G Priori, Carlo Napolitano, Aharon Medina, Li Zhang, Jennifer L Robinson, Katherine Timothy, Jeffrey A Towbin, Mark L Andrews
2000-02-15
Abstract:Background—β-blockers are routinely prescribed in congenital long-QT syndrome (LQTS), but the effectiveness and limitations of β-blockers in this disorder have not been evaluated. Methods and Results—The study population comprised 869 LQTS patients treated with β-blockers. Effectiveness of β-blockers was analyzed during matched periods before and after starting β-blocker therapy, and by survivorship methods to determine factors associated with cardiac events while on prescribed β-blockers. After initiation of β-blockers, there was a significant (P<0.001) reduction in the rate of cardiac events in probands (0.97±1.42 to 0.31±0.86 events per year) and in affected family members (0.26±0.84 to 0.15±0.69 events per year) during 5-year matched periods. On-therapy survivorship analyses revealed that patients with cardiac symptoms before β-blockers (n=598) had a hazard ratio of 5.8 (95% CI, 3.7 to 9.1) for …
What problem does this paper attempt to address?